抗生素治疗有效的储袋炎患者肠道菌群以耐药菌为主且持续存在
这项前瞻性研究纳入49例储袋手术患者,收集234份粪便样本,发现抗生素治疗储袋炎虽使79%患者临床应答,但89%在4周疗程后3个月内复发;抗生素选择出低炎症潜力的耐药菌群,停药后口腔及致病菌激增,多重耐药基因富集。
要点
- 抗生素治疗储袋炎临床应答率高但复发率也高,易发展为抗生素依赖。
- 应答者菌群以需氧兼性厌氧菌为主,携带环丙沙星耐药突变且体外证实耐药。
- 耐药菌群炎症潜力低,但停药后迅速被口腔及致病菌占据并富集多重耐药基因。
核心结论
- 抗生素治疗储袋炎的疗效可能源于建立低炎症潜力的耐药菌群,该菌群可抵抗促炎菌定植。
- 为避免进展为抗生素依赖性疾病及其后果,应考虑短期交替抗生素及营养和微生物组干预策略。
研究设计与样本
- 前瞻性研究,纳入49例在三级中心行储袋手术的患者,包括复发性急性储袋炎6例、慢性储袋炎及储袋克罗恩样病27例、溃疡性结肠炎正常储袋10例、家族性腺瘤性息肉病正常储袋6例。
- 采用临床、内镜和组织学标准判定疾病活动度,测量钙卫蛋白,并采用鸟枪法宏基因组测序及专门设计的生物信息学流程分析粪便DNA。
- 从粪便样本分离细菌菌株,评估其环丙沙星耐药性及诱导HT-29肠上皮细胞分泌炎症因子的能力。
主要发现
- 大多数(79%)接受抗生素治疗的患者对每个疗程有临床应答,但完成4周疗程者中89%在3个月内复发。
- 抗生素治疗使中位钙卫蛋白水平下降40%。
- 抗生素治疗减少了产气荚膜梭菌、瘤胃球菌和肺炎克雷伯菌等疾病相关细菌,但也减少了普拉梭菌等有益菌。
- 抗生素应答者的微生物组以埃希菌属、肠球菌属和链球菌属等兼性厌氧菌为主,药物靶基因存在多个环丙沙星耐药突变且耐药性经确认。
- 这些耐药菌株毒力潜力较低,且不诱导上皮细胞分泌炎症因子;停药后菌群组成急剧转变,口腔及疾病相关细菌大量繁殖。
临床怎么用
- 储袋炎抗生素治疗应答者虽临床改善,但复发率高,需警惕抗生素依赖。
- 可考虑短期交替抗生素及营养和微生物组干预策略,以减少抗生素依赖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pouchitis that develops in patients with ulcerative colitis after total proctocolectomy and ileal pouch anal anastomosis is usually treated with antibiotics. Some patients have recurrence of flares, or become antibiotic-dependent, and require repeated courses or prolonged periods of antibiotic therapy. We investigated microbial factors associated with response to antibiotic treatment and development of antibiotic dependence in patients with pouchitis. METHODS: We performed a prospective study of 49 patients who had undergone pouch surgery at a tertiary center. Disease activity was determined based on clinical, endoscopic, and histologic criteria. Pouch phenotype was defined as recurrent-acute pouchitis (n = 6), chronic pouchitis and Crohn's-like disease of the pouch (n = 27), normal pouch from patient with ulcerative colitis (n = 10), and normal pouch from patient with familial adenomatous polyposis (n = 6). Fecal samples (n = 234) were collected over time during or in the absence of antibiotic treatment (ciprofloxacin and/or metronidazole). Thirty-three patients were treated with antibiotics, for a median of 425 days of cumulative antibiotic therapy, during follow-up. Calprotectin was measured and fecal DNA was sequenced using shotgun metagenomics and analyzed with specifically designed bioinformatic pipelines. Bacterial strains were isolated from fecal samples. We assessed their ciprofloxacin resistance and ability to induce secretion of inflammatory cytokines by HT-29 intestinal epithelial cells. RESULTS: Most antibiotic-treated patients (79%) had a clinical response to each course of antibiotics; however, 89% of those who completed a 4-week course relapsed within 3 months. Median calprotectin levels decreased by 40% in response to antibiotics. Antibiotic treatment reduced disease-associated bacteria such as Clostridium perfringens, Ruminococcus gnavus, and Klebsiella pneumoniae, but also beneficial species, such as Faecalibacterium prausnitzii. The microbiomes of antibiotic-responsive patients were dominated by facultative anaerobic genera (Escherichia, Enterococcus, and Streptococcus), with multiple ciprofloxacin-resistance mutations in drug target genes and confirmed drug resistance. However, these strains had lower potential for virulence and did not induce secretion of inflammatory cytokines by epithelial cells. After antibiotic cessation, patients had an abrupt shift in microbiome composition, with blooms of oral and disease-associated bacteria. In addition, antibiotic treatment enriched for strains that acquired multidrug resistance loci, encoding enzymes that confer resistance to nonrelated antibiotics, including extended-spectrum beta-lactamases. CONCLUSIONS: The efficacy of antibiotic treatment of pouchitis might be attributed to the establishment of an antibiotic-resistant microbiome with low inflammatory potential. This microbiome might provide resistance against colonization by bacteria that promote inflammation. To avoid progression to antibiotic-dependent disease and its consequences, strategies such as short-term alternating antibiotics and nutrition- and microbiome-based interventions should be considered.
引用
- Dubinsky V, Reshef L, Bar N, et al. Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. Gastroenterology. 2019. PMID: 31605691. doi:10.1053/j.gastro.2019.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。